arrow
J

Jordi Ochando

instituto de salud carlos iii
H指数:48
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A tumor-selective mRNA system enables precision cancer treatment

一种肿瘤选择性mRNA系统能够实现精准癌症治疗

2025-11-150
PRE
Systematic production of human kidney organoids for transplantation in porcine kidneys during ex vivo machine perfusion

系统性生产用于在离体机器灌注期间移植到猪肾脏的人肾类器官

2025-10-310
OAAI
Pharmacological inhibition of Epac1 protects against pulmonary fibrosis by blocking FoxO3a neddylation

Epac1的药理学抑制通过阻断FoxO3a的neddylation来保护 against 肺纤维化

2025-10-010
PRE
In vitro protocol demonstrating five functional steps of trained immunity in mice: Implications on biomarker discovery and translational research

体外实验方案展示小鼠训练免疫的五个功能步骤:对生物标志物发现和转化研究的意义

2025-09-260
PREAI
Swine influenza-modified pulmonary microbiota

猪流感修饰的肺微生物群

2025-09-080
OA
Ex Vivo IL-15-Stimulated NK Cells as Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Leukemia

异体移植中用于儿童白血病的离体IL-15刺激的NK细胞作为过继细胞疗法

2025-08-080
PREAI
Data Interoperability in COVID-19 Vaccine Trials: Methodological Approach in the VACCELERATE Project

新型冠状病毒肺炎疫苗试验中的数据互操作性: VACCELERATE项目中的方法学方法

2025-01-010
OAAI
Trained immunity suppression determines kidney survival

训练有素的免疫抑制决定肾脏存活率

2024-11-010
PRE
Trained immunity is regulated by T cell-induced CD40-TRAF6 signaling

训练免疫受T细胞诱导的CD40-TRAF6信号调节

2024-09-011
OAAI
Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE Survey Study

欧洲患者倡导团体对志愿者注册和疫苗试验的看法: VACCELERATE调查研究

2024-04-041
OAAI
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium

服务不足和难以到达的社区参与疫苗试验的挑战: VACCELERATE联盟的内部专家咨询

2023-11-293
OAAI
Maintenance of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients after 1273-mRNA SARS-CoV-2 Vaccination

1273 mRNA SARS-CoV-2疫苗接种后,长期血液透析患者有效的细胞和体液免疫反应的维持

2023-04-113
OAAI
Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit
2023-04-034
OAAI
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
2022-08-014
OAAI
Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR
2022-06-1327
OA